The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures

被引:10
作者
Shi, Tao [1 ]
Zhu, Shuai [2 ]
Guo, Hengjuan [3 ]
Li, Xiongfei [2 ]
Zhao, Shikang [2 ]
Wang, Yanye [2 ]
Lei, Xi [2 ]
Huang, Dingzhi [4 ]
Peng, Ling [5 ]
Li, Ziming [6 ]
Xu, Song [2 ]
机构
[1] Tianjin Med Univ Gen Hosp, Precis Med Ctr, Tianjin, Peoples R China
[2] Tianjin Med Univ Gen Hosp, Dept Lung Canc Surg, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Lung Canc Inst, Tianjin, Peoples R China
[3] Tianjin Med Univ Gen Hosp, Dept Resp & Crit Care, Tianjin, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[5] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Radiotherapy, Hangzhou, Peoples R China
[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-L1; NSCLC; meta-analysis; prognosis; resection; PD-L1; EXPRESSION; SURVIVAL;
D O I
10.3389/fonc.2021.567978
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Previous studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit of PD-L1 expression to predict the prognosis of early stage NSCLC patients who underwent complete resection remains controversial. In the present study, we performed a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in patients with early stage resected NSCLC. Methods Electronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched until July 23 2020 for studies evaluating the expression of PD-L1 and the prognosis of resected NSCLCs. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS) were pooled and analyzed. Heterogeneity and publication bias analyses were also assessed. Results A total of 15 studies involving 3,790 patients were considered in the present meta-analysis. The pooled HR indicated that PD-L1 expression related to a much shorter DFS (HR = 1.56, 95% CI: 1.18-2.05, p < 0.01), as well a significantly worse OS (HR = 1.68, 95% CI: 1.29-2.18, p < 0.01). Furthermore, our analysis indicated that PD-L1 expression was significantly associated with gender (male vs. female: OR = 1.27, 95% CI:1.01-1.59, p = 0.038), histology (ADC vs. SCC: OR = 0.54, 95% CI:0.38-0.77, p = 0.001), TNM stage (I vs. II-III: OR = 0.45, 95% CI:0.34-0.60, p = 0.000), smoking status (Yes vs No: OR = 1.43, 95% CI:1.14-1.80, p = 0.002) and lymph node metastasis (N+ vs N-: OR = 1.97, 95% CI:1.26-3.08, p = 0.003). Conclusions The results of this meta-analysis suggest that PD-L1 expression predicts an unfavorable prognosis in early stage resected NSCLCs. The role of personalized anti-PD-L1/PD-1 immunotherapy in the adjuvant settings of resected NSCLC warrants further investigation.
引用
收藏
页数:8
相关论文
共 39 条
[1]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[2]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[3]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[4]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[5]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[6]   PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level [J].
Cao, Lianjing ;
Wang, Xinyue ;
Li, Shouying ;
Zhi, Qiongjie ;
Wang, Yuqian ;
Wang, Liuchun ;
Li, Kai ;
Jiang, Richeng .
JOURNAL OF CANCER, 2017, 8 (16) :3251-3260
[7]   A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy [J].
Dinnes, J ;
Deeks, J ;
Kirby, J ;
Roderick, P .
HEALTH TECHNOLOGY ASSESSMENT, 2005, 9 (12) :1-+
[8]   Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma [J].
Gachechiladze, Mariam ;
Skarda, Josef ;
Skanderova, Daniela ;
Uberall, Ivo ;
Kolek, Vitezslav ;
Smickova, Petra ;
Vojta, Petr ;
Vbrkova, Jana ;
Hajduch, Marian ;
Shani, Ilay ;
Kolar, Zdenek ;
Stahel, Rolf ;
Weder, Walter ;
Rulle, Undine ;
Soltermann, Alex ;
Joerger, Markus .
LUNG CANCER, 2020, 147 :30-38
[9]   The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J].
Goldstraw, Peter ;
Chansky, Kari ;
Crowley, John ;
Rami-Porta, Ramon ;
Asamura, Hisao ;
Eberhardt, Wilfried E. E. ;
Nicholson, Andrew G. ;
Groome, Patti ;
Mitchell, Alan ;
Bolejack, Vanessa .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :39-51
[10]   Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].
Herbst, Roy S. ;
Baas, Paul ;
Kim, Dong-Wan ;
Felip, Enriqueta ;
Perez-Gracia, Jose L. ;
Han, Ji-Youn ;
Molina, Julian ;
Kim, Joo-Hang ;
Arvis, Catherine Dubos ;
Ahn, Myung-Ju ;
Majem, Margarita ;
Fidler, Mary J. ;
de Castro, Gilberto, Jr. ;
Garrido, Marcelo ;
Lubiniecki, Gregory M. ;
Shentu, Yue ;
Im, Ellie ;
Dolled-Filhart, Marisa ;
Garon, Edward B. .
LANCET, 2016, 387 (10027) :1540-1550